Download Image
    
Share
  
Post
rNAPc2 for COVID-19
1 study with 156 patients
Hospital Icon Control
Hospital Icon rNAPc2 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 rNAPc2 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -65% Mortality -65% RCTs -65% Late -65% FavorsrNAPc2 Favorscontrol
Aug 31
2023
 Hess et al., Arteriosclerosis, Thrombosis, and Vascular Biology, doi:10.1161/ATVBAHA.122.318748 Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial
65% higher mortality (p=0.32). RCT 160 hospitalized COVID-19 patients showing no significant improvements with rNAPc2 (recombinant nematode anticoagulant protein c2) vs. heparin.